549 related articles for article (PubMed ID: 24145643)
21. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K
Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644
[TBL] [Abstract][Full Text] [Related]
22. Strong androgen receptor expression is not useful in distinguishing GATA3 + metastases.
Lionti S; La Rocca L; Nunnari CM; Barresi V
Pathol Res Pract; 2018 Dec; 214(12):2110-2114. PubMed ID: 30293951
[TBL] [Abstract][Full Text] [Related]
23. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
Wendroth SM; Mentrikoski MJ; Wick MR
Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392
[TBL] [Abstract][Full Text] [Related]
24. GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.
Reiswich V; Schmidt CE; Lennartz M; Höflmayer D; Hube-Magg C; Weidemann S; Fraune C; Büscheck F; Möller K; Bernreuther C; Simon R; Clauditz TS; Blessin NC; Bady E; Sauter G; Uhlig R; Steurer S; Minner S; Burandt E; Dum D; Marx AH; Krech T; Lebok P; Hinsch A; Jacobsen F
Pathobiology; 2023; 90(4):219-232. PubMed ID: 36649695
[TBL] [Abstract][Full Text] [Related]
25. A study of gata3 and phox2b expression in tumors of the autonomic nervous system.
Nonaka D; Wang BY; Edmondson D; Beckett E; Sun CC
Am J Surg Pathol; 2013 Aug; 37(8):1236-41. PubMed ID: 23715162
[TBL] [Abstract][Full Text] [Related]
26. Endosalpingiosis Is Negative for GATA3.
White MJ; Vang R; Argani P; Cimino-Mathews A
Arch Pathol Lab Med; 2021 Nov; 145(11):1448-1452. PubMed ID: 33571371
[TBL] [Abstract][Full Text] [Related]
27. GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung.
Berg KB; Churg A
Am J Surg Pathol; 2017 Sep; 41(9):1221-1225. PubMed ID: 28614203
[TBL] [Abstract][Full Text] [Related]
28. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
29. Strong androgen receptor expression can aid in distinguishing GATA3+ metastases.
Boto A; Harigopal M
Hum Pathol; 2018 May; 75():63-70. PubMed ID: 29408697
[TBL] [Abstract][Full Text] [Related]
30. The Diagnostic Dilemma of GATA3 Immunohistochemistry in Pheochromocytoma and Paraganglioma.
Kimura N; Shiga K; Kaneko K; Sugisawa C; Katabami T; Naruse M
Endocr Pathol; 2020 Jun; 31(2):95-100. PubMed ID: 32303954
[TBL] [Abstract][Full Text] [Related]
31. The role of GATA3 in breast carcinomas: a review.
Asch-Kendrick R; Cimino-Mathews A
Hum Pathol; 2016 Feb; 48():37-47. PubMed ID: 26772397
[TBL] [Abstract][Full Text] [Related]
32. Application of mesothelin immunostaining in tumor diagnosis.
Ordóñez NG
Am J Surg Pathol; 2003 Nov; 27(11):1418-28. PubMed ID: 14576474
[TBL] [Abstract][Full Text] [Related]
33. GATA3 expression in gestational trophoblastic tissues and tumours.
Mirkovic J; Elias K; Drapkin R; Barletta JA; Quade B; Hirsch MS
Histopathology; 2015 Nov; 67(5):636-44. PubMed ID: 25753145
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas.
Liu H; Shi J; Wilkerson ML; Lin F
Am J Clin Pathol; 2012 Jul; 138(1):57-64. PubMed ID: 22706858
[TBL] [Abstract][Full Text] [Related]
35. Utility of uroplakin II expression as a marker of urothelial carcinoma.
Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
[TBL] [Abstract][Full Text] [Related]
36. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer.
Ai D; Yao J; Yang F; Huo L; Chen H; Lu W; Soto LMS; Jiang M; Raso MG; Wang S; Bell D; Liu J; Wang H; Tan D; Torres-Cabala C; Gan Q; Wu Y; Albarracin C; Hung MC; Meric-Bernstam F; Wistuba II; Prieto VG; Sahin AA; Ding Q
Mod Pathol; 2021 Apr; 34(4):710-719. PubMed ID: 33011748
[TBL] [Abstract][Full Text] [Related]
37. GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma.
So JS; Epstein JI
Mod Pathol; 2013 Oct; 26(10):1365-70. PubMed ID: 23599157
[TBL] [Abstract][Full Text] [Related]
38. GATA3 Expression in Common Gynecologic Carcinomas: A Potential Pitfall.
Terzic T; Mills AM; Zadeh S; Atkins KA; Hanley KZ
Int J Gynecol Pathol; 2019 Sep; 38(5):485-492. PubMed ID: 30059453
[TBL] [Abstract][Full Text] [Related]
39. GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.
Piao ZH; Zhou XC; Chen JY
Virchows Arch; 2021 Aug; 479(2):257-263. PubMed ID: 33570661
[TBL] [Abstract][Full Text] [Related]
40. GATA3 as a valuable marker to distinguish clear cell papillary renal cell carcinomas from morphologic mimics.
Mantilla JG; Antic T; Tretiakova M
Hum Pathol; 2017 Aug; 66():152-158. PubMed ID: 28705707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]